Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index; 25 of the 158 sources its claims cite were checked for support.
Abstract
Central hypogonadism is a clinical condition, characterized by sexual symptoms and low serum testosterone levels, due to an impaired function of the hypothalamus or pituitary gland. Testosterone replacement therapy (TRT) is the standard treatment for hypogonadism, but it has some disadvantages. TRT is not a good option in men wishing to preserve fertility, nor in men with (a high risk of) prostate cancer, polycythemia, thrombophilia and severe cardiovascular disease. In this review, we discuss alternative treatments for central hypogonadism. If reversible causes are present, non-pharmacological interventions can be therapeutic. Gonadotropins are a good alternative to TRT when fertility is desired in the near future though they require frequent injections. Clomiphene citrate and tamoxifen seem to be a safe alternative for the treatment of functional central hypogonadism in men, as several studies reported a significant increase in testosterone levels with these drugs. However, their use is off-label and data supporting the efficacy of clomiphene citrate and tamoxifen on hypogonadal symptoms are insufficient. For this reason, clomiphene citrate and tamoxifen should not be used in routine clinical practice to treat sexual symptoms in men with central hypogonadism.
Overview
CoChat Summary
## TL;DR
This review summarizes alternatives to testosterone replacement therapy (TRT) for men with central hypogonadism, especially when fertility must be preserved or TRT is otherwise unsuitable. The authors conclude that gonadotropins are the best-supported alternative for fertility-directed treatment, while clomiphene citrate and tamoxifen may raise testosterone in functional central hypogonadism but should not be used routinely for sexual symptoms because symptom-benefit data are insufficient.
## Key findings
- TRT is described as the standard treatment for hypogonadism, but it is not a good option for men wishing to preserve fertility and is contraindicated or unsuitable in men with prostate cancer risk, polycythemia, thrombophilia, severe cardiovascular disease, and some other conditions.
- Gonadotropin therapy induced spermatogenesis in 75% of patients in one meta-analysis of men with hypogonadotropic hypogonadism and azoospermia; in another combined analysis of 100 patients, spermatogenesis was induced in 84% and 69% reached sperm concentrations ≥1.5 × 10^6/mL.
- A retrospective study in hypogonadotropic hypogonadism found hCG alone led to testicular growth in 42/84 (50%) and spermatogenesis in 34/84 (40%), while hCG + hMG led to testicular growth in 56/74 (76%) and spermatogenesis in 48/74 (65%).
- Clomiphene citrate and tamoxifen were reported in several studies to significantly increase testosterone, but evidence for symptom improvement is inconsistent; one study in 86 men showed improvement in 5/10 ADAM questions, while an RCT in 78 obese men found no difference in overall ADAM score after 12 weeks.
- In one retrospective analysis of 400 men treated with clomiphene citrate for a mean of 25.5 months, side effects were reported in 8%; another study of 46 men reported no side effects over 12 months.
## Methods
- This is a narrative review of treatments for central hypogonadism, organized into non-pharmacological interventions, gonadotropins, pulsatile GnRH, SERMs (clomiphene citrate, tamoxifen), and aromatase inhibitors.
- The paper synthesizes evidence from studies cited in the text, including meta-analyses, randomized controlled trials, retrospective studies, and small observational studies; no new patient sample is presented.
- The main analysis is qualitative comparison of treatment options based on effects on testosterone, fertility/spermatogenesis, hypogonadal symptoms, and adverse effects.
## Limitations
- The paper states that studies of clomiphene citrate and tamoxifen are often heterogeneous, frequently lack clear descriptions of the study population, and often do not distinguish organic from functional central hypogonadism.
- It explicitly notes that high-quality RCTs with clear population definitions and long-term follow-up are missing for clomiphene citrate and tamoxifen, so evidence is insufficient to justify their routine use for sexual symptoms.
- Evident from the text: this is a review, so conclusions depend on the quality and consistency of previously published studies rather than direct original data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
23 Valid · 0 Not valid · 89 Not checked · 16 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“As functional hypogonadism is associated with the use of certain drugs, hyperprolactinemia, obesity and chronic diseases, such as type 2 diabetes, treatment of these causes can help normalize testosterone levels [9].”
§ Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy > 2. Non-Pharmacological Treatment
What the sources say
- Partly supportedcites [9] Grossmann, 2017, A Perspective on Middle-Aged and Older Men with Functional Hypogonadism: Focus on Holistic Management, J. Clin. Endocrinol. Metab. sourceExperimental — accuracy not yet measured
The Abstract (page not provided) links functional hypogonadism to obesity, comorbid illness, and medications such as opioids or glucocorticoids; “Optimization of Chronic Disease” specifically identifies type 2 diabetes. The paper says these conditions may improve with treatment, but its definition excludes hyperprolactinemia as a specific pathologic cause that should be ruled out. (LLM, conf=0.90)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“As functional hypogonadism is associated with the use of certain drugs, hyperprolactinemia, obesity and chronic diseases, such as type 2 diabetes, treatment of these causes can help normalize testosterone levels [9].”
§ Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy > 2. Non-Pharmacological Treatment
What the sources say
- Partly supportedcites [9] Grossmann, 2017, A Perspective on Middle-Aged and Older Men with Functional Hypogonadism: Focus on Holistic Management, J. Clin. Endocrinol. Metab. sourceExperimental — accuracy not yet measured
The Conclusions (page unavailable) say that weight loss and management of comorbidities may reverse HPT-axis suppression enough to normalize testosterone; stopping offending medications may also increase levels, though these measures may be insufficient. The Abstract (page unavailable) treats hyperprolactinemia differently: it is a specific pathology to exclude from the paper’s defined group of men with functional hypogonadism, not one of the causes addressed by those management recommendations. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Moreover, the role of TRT to treat men with functional or late-onset hypogonadism remains controversial because of unclear indications and potential side effects [1,9].”
§ Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [1] Salonia, 2019, Paediatric and adult-onset male hypogonadism, Nat. Rev. Dis. Prim. source
- Supportedcites [9] Grossmann, 2017, A Perspective on Middle-Aged and Older Men with Functional Hypogonadism: Focus on Holistic Management, J. Clin. Endocrinol. Metab. source
The Testosterone Therapy section says decisions about TRT must weigh uncertain long-term benefits and risks, exclude contraindications, and target men with specific symptoms and consistently low testosterone. The Characteristics section explains why symptoms and low testosterone do not always establish androgen deficiency, supporting the claim that indications are unclear. Page numbers were not provided in our copy. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Several studies with a very low-calorie ketogenic diet showed a positive effect of this diet on body mass index, glycemic control and insulin resistance.”
§ Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy > 2. Non-Pharmacological Treatment
What the sources say
- Supportedcites [23] Mongioì, L.M., Cimino, L., Condorelli, R.A., Magagnini, M.C., Barbagallo, F., Cannarella, R., la Vignera, S., and Calogero, A.E. (2020). Effectiveness of a Very Low Calorie Ketogenic Diet on Testicular Function in Overweight/Obese Men. Nutrients, 12. source
The Results report significant improvements in BMI, fasting glucose, insulin, and HOMA index after VLCKD. The Discussion also describes previous studies finding BMI reductions and a review reporting improved glycemic control and a lower HOMA index. (LLM, conf=0.91)
- Supportedcites [24] La Vignera, S., Cannarella, R., Galvano, F., Grillo, A., Aversa, A., Cimino, L., Magagnini, C.M., Mongioì, L.M., Condorelli, R.A., and Calogero, A.E. (2020). The ketogenic diet corrects metabolic hypogonadism and preserves pancreatic ß-cell function in overweight/obese men: A single-arm uncontrolled study. Endocrine, 1–8. source
The Results report significant decreases in BMI, glycaemia, and the HOMA index after a very low-calorie ketogenic diet. The Discussion also reports that several studies found improvements in glycaemic measures and insulin resistance. The study itself was single-arm and uncontrolled, so its before-and-after results do not establish causation on their own. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A small study in 20 patients with overweight or obesity and functional hypogonadism showed that a very low-calorie ketogenic diet during 12 weeks resulted in a mean increase in total testosterone levels of around 218% (± 53.9%) [24].”
§ Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy > 2. Non-Pharmacological Treatment
What the sources say
- Supportedcites [24] La Vignera, S., Cannarella, R., Galvano, F., Grillo, A., Aversa, A., Cimino, L., Magagnini, C.M., Mongioì, L.M., Condorelli, R.A., and Calogero, A.E. (2020). The ketogenic diet corrects metabolic hypogonadism and preserves pancreatic ß-cell function in overweight/obese men: A single-arm uncontrolled study. Endocrine, 1–8. source
The Abstract Results (page not provided) report 20 patients and a mean 218.1 ± 53.9% increase in total testosterone. The Abstract Methods (page not provided) specify that the patients had overweight or obesity and metabolic hypogonadism and followed a very low-calorie ketogenic diet for 12 weeks. (LLM, conf=0.95)
plainstates a causen = 20- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
82 more claims · 11 with their cited sources checked
Create a free account to see all 128 claims and to verify the 11 references still open.
- It may state two separate claims as one. 33
- Probably not a substantial claim. 9
Citations
Cites
Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Wu, F. C., & Yialamas, M. A. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00229 · Cited by 1,736 · cited 10×
“According to the Endocrine Society and European Academy of Andrology guidelines, only men with symptoms or signs of testosterone deficiency and repeatedly low serum testosterone concentrations on morning blood samples, taken in standardized conditions, should be diagnosed with hypogonadism [2,3].”
BackgroundMethodInfluentialIdentification of late-onset hypogonadism in middle-aged and elderly men
Wu, F. C. W., Tajar, A., Beynon, J. M., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F. F., Forti, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911101 · Cited by 1,544 · cited 1×
“Therefore, the European Male Aging Study (EMAS) group suggests that only ageing men with concomitantly low total and free serum testosterone levels, and at least three sexual symptoms should be diagnosed with late-onset hypogonadism [10,11].”
BackgroundSelf-citationWu, F. C. W., Tajar, A., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F., Forti, G., Giwercman, A., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1972 · Cited by 939 · cited 1×
“This clinical syndrome is associated with obesity, metabolic syndrome and chronic diseases [12,13].”
BackgroundSelf-citationBoehm, U., Bouloux, P.-M., Dattani, M. T., de Roux, N., Dodé, C., Dunkel, L., Dwyer, A. A., Giacobini, P., Hardelin, J.-P., Juul, A., et al. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.112 · Cited by 874 · cited 5×
“For this reason, combined gonadotropin treatment is preferred over hCG monotherapy in patients with a lack of testicular development [5].”
BackgroundInfluentialEffect of Lifestyle Changes on Erectile Dysfunction in Obese Men: A Randomized Controlled Trial
Esposito, K., Giugliano, F., Di Palo, C., Giugliano, G., Marfella, R., D'Andrea, F., D'Armiento, M., & Giugliano, D. (2004) · JAMA · doi:10.1001/jama.291.24.2978 · Cited by 841 · cited 1×
“Furthermore, weight loss by lifestyle modifications is associated with improvement in sexual function, measured by the International Index of Erectile Function [25].”
MethodBacon, C. G., Mittleman, M. A., Kawachi, I., Giovannucci, E., Glasser, D. B., & Rimm, E. B. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-3-200308050-00005 · Cited by 832 · cited 1×
“Obesity increases the risk of erectile dysfunction in this population with 30% [19].”
BackgroundCorona, G., Goulis, D. G., Huhtaniemi, I., Zitzmann, M., Toppari, J., Forti, G., Vanderschueren, D., & Wu, F. C. (2020) · Andrology · doi:10.1111/andr.12770 · Cited by 431 · cited 3×
“According to the Endocrine Society and European Academy of Andrology guidelines, only men with symptoms or signs of testosterone deficiency and repeatedly low serum testosterone concentrations on morning blood samples, taken in standardized conditions, should be diagnosed with hypogonadism [2,3].”
BackgroundMethodSelf-citationCorona, G., Rastrelli, G., Monami, M., Saad, F., Luconi, M., Lucchese, M., Facchiano, E., Sforza, A., Forti, G., Mannucci, E., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-12-0955 · Cited by 414
Travison, T. G., Araujo, A. B., Kupelian, V., O’Donnell, A. B., & McKinlay, J. B. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1859 · Cited by 410
Camacho, E. M., Huhtaniemi, I. T., O'Neill, T. W., Finn, J. D., Pye, S. R., Lee, D. M., Tajar, A., Bartfai, G., Boonen, S., Casanueva, F. F., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-12-0890 · Cited by 392
Self-citation
Cited by
Insights and implications of sexual dimorphism in osteoporosis
Zhang, Y., Xie, N., Sun, X., Nice, E. C., Liou, Y., Huang, C., Zhu, H., & Shen, Z. (2024) · Bone Research · doi:10.1038/s41413-023-00306-4 · Cited by 184
Jin, J., Xu, Z., Zhang, L., Zhang, C., Zhao, X., Mao, Y., Zhang, H., Liang, X., Wu, J., Yang, Y., et al. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2167172 · Cited by 136
Roychoudhury, S., Chakraborty, S., Choudhury, A. P., Das, A., Jha, N. K., Sláma, P., Nath, M., Massányi, P., Ruokolainen, J., & Kesari, K. K. (2021) · Antioxidants · doi:10.3390/antiox10060837 · Cited by 145
Kharbech, O., Sakouhi, L., Massoud, M. B., Mur, L. A. J., Corpas, F. J., Djebali, W., & Chaoui, A. (2020) · Plant Physiology and Biochemistry · doi:10.1016/j.plaphy.2020.10.017 · Cited by 106
The emerging roles of bacterial proteases in intestinal diseases
Caminero, A., Guzman, M., Libertucci, J., & Lomax, A. E. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2181922 · Cited by 92
Xing, D., Xia, G., Tang, X.-D., Zhuang, Z., Shan, J., Fang, X., Qiu, L., Zha, X., & Chen, X. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202401619 · Cited by 51
Stool multi-omics for the study of host–microbe interactions in inflammatory bowel disease
Sauceda, C., Bayne, C. F., Sudqi, K., González, A., Dulai, P. S., Knight, R. D., Gonzalez, D. J., & Gonzalez, C. G. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2154092 · Cited by 41
An Update on Advances in Hypopituitarism: Etiology, Diagnosis, and Current Management
Iglesias, P. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13206161 · Cited by 43
Liao, X., Shen, M., Li, T., Li, F., Zhao, L., Shi, G., Pei, G., & Cai, X. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s428429 · Cited by 36
New perspectives in functional hypogonadotropic hypogonadism: beyond late onset hypogonadism
Spaziani, M., Carlomagno, F., Tarantino, C., Angelini, F., Vincenzi, L., & Gianfrilli, D. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1184530 · Cited by 41
Current Perspectives: Obesity and Neurodegeneration - Links and Risks
Kueck, P. J., Morris, J. K., & Stanford, J. A. (2024) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s388579 · Cited by 37
Testosterone recovery therapy targeting dysfunctional Leydig cells
Garza, S., & Papadopoulos, V. (2022) · Andrology · doi:10.1111/andr.13304 · Cited by 31
Mechanisms of Postischemic Stroke Angiogenesis: A Multifaceted Approach
Hu, B., Pei, J., Wan, C., Liu, S., Xu, Z., Zou, Y., Li, Z., & Tang, Z. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s461427 · Cited by 34
Role and Mechanism of Growth Differentiation Factor 15 in Chronic Kidney Disease
Tang, Y., Liu, T., Sun, S., Peng, Y.-B., Huang, X., Wang, S., & Zhou, Z. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s451398 · Cited by 34
Baron, K. J., & Turnquist, H. R. (2023) · Organogenesis · doi:10.1080/15476278.2022.2164159 · Cited by 27
Chung, E., Jiang, H., Xin, Z. C., Kim, S. W., Moon, D. G., Yuan, Y., Nagao, K., Hakim, L., Chang, H., Mak, S. K., et al. (2023) · The World Journal of Men s Health · doi:10.5534/wjmh.230180 · Cited by 27
Cuproptosis Cell Death Molecular Events and Pathways to Liver Disease
Mao, Y., Chen, H., Zhu, W., Ni, S., Luo, S., Tang, S., Chen, Z., Wang, Q., Xu, J., Tu, Q., et al. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s498340 · Cited by 17
Yang, Y., Yang, S., Zhang, B., Wang, J., Meng, D., Cui, L., & Zhang, L. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s472276 · Cited by 23
The Role of Intestinal Flora and Its Metabolites in Heart Failure
Guan, X., & Sun, Z. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s390582 · Cited by 19
Kaltsas, A. (2025) · Cells · doi:10.3390/cells14120899 · Cited by 26
Wu, Y., & Sung, W. (2024) · Pharmaceuticals · doi:10.3390/ph17091233 · Cited by 21
Hou, P., Yang, Y., Li, Z., Ye, D., Chen, L., Feng, T., Zeng, J., Wei, L., & Wang, S. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s454099 · Cited by 18
Liu, Z., Wang, Z., Zhu, Z., Hong, J., Cui, L., Hao, Y., Cheng, G., & Tan, R. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202203132 · Cited by 19
Pharmacological therapies for male infertility
Rambhatla, A., Shah, R. S., Pinggera, G., Mostafa, T., Atmoko, W., Saleh, R. A., Chung, E., Hamoda, T. A.-A. A.-M., Çayan, S., Park, H. J., et al. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.001085 · Cited by 21
Dong, M., Chen, H., Wen, S., Yuan, Y., Yang, L., Li, Y., Yuan, X., Xu, D., & Zhou, L. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s399367 · Cited by 20
Tienforti, D., Castellini, C., Giulio, F. D., Totaro, M., Dalmazio, G., Spagnolo, L., Muselli, M., Corona, G., Baroni, M. G., & Barbonetti, A. (2023) · Andrology · doi:10.1111/andr.13373 · Cited by 17
Ceccato, F., Lizzul, L., Voltan, G., Barbot, M., & Scaroni, C. M. (2021) · Pituitary · doi:10.1007/s11102-021-01165-0 · Cited by 15
Acupuncture-Related Therapy for Knee Osteoarthritis: A Narrative Review of Neuroimaging Studies
Qu, Y.-Z., Peng, Y., Xiong, Y., Dong, X., Ma, P., & Cheng, S.-R. (2024) · Journal of Pain Research · doi:10.2147/jpr.s450515 · Cited by 15
The effect of red blood cell disorders on male fertility and reproductive health
Naelitz, B. D., Khooblall, P., Parekh, N. V., Vij, S. C., Rotz, S. J., & Lundy, S. D. (2024) · Nature Reviews Urology · doi:10.1038/s41585-023-00838-8 · Cited by 16
Therapeutic Use and Chronic Abuse of CNS Stimulants and Anabolic Drugs
Coliță, D., Coliță, C.-I., Hermann, D. M., Coliță, E., Doeppner, T. R., Udriștoiu, I., & Popa‐Wagner, A. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44100333 · Cited by 16
The role of clomiphene citrate in late onset male hypogonadism
Ros, C. T. D., Ros, L. U. D., & da Ros, J. P. U. (2022) · International braz j urol · doi:10.1590/s1677-5538.ibju.2021.0724 · Cited by 16
Song, C., Song, W., Liu, Y., Zhou, D., Cai, W., Mei, Y., Liu, F., Jiang, F., Chen, F., & Liu, Z. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s503618 · Cited by 12
Li, H., Liang, C., Kuang, D., Huang, G., Zhang, M., Chen, P., Zheng, Q., Xu, W., Ren, J., Han, X., et al. (2023) · Cancer Biology & Therapy · doi:10.1080/15384047.2023.2166335 · Cited by 12
Kharbech, O., Massoud, M. B., Chaoui, A., Mur, L. A. J., & Djebali, W. (2021) · Journal of Plant Growth Regulation · doi:10.1007/s00344-021-10411-5 · Cited by 12
Khera, M., Torres, L. O., Grober, E. D., Morgentaler, A., Miner, M. M., Jones, T. H., Mills, J. N., & Salonia, A. (2025) · Sexual Medicine Reviews · doi:10.1093/sxmrev/qeaf036 · Cited by 26
Mechanisms of Leydig Cell Aging and Obesity-Related Hypogonadism in Men: A Review
Huang, X., Zhao, H., Wu, X., Liang, Y., Guan, Q., Luo, D., & Yu, C. (2025) · Medical Science Monitor · doi:10.12659/msm.948180 · Cited by 17
Pharmacotherapy of male hypogonadism
Rastrelli, G., Vignozzi, L., Corona, G., & Maggi, M. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102323 · Cited by 14
The Effects of Tamoxifen on Tolerogenic Cells in Cancer
Idris, R. A. M., Mussa, A., Ahmad, S., Al-Hatamleh, M. A. I., Hassan, R., Din, T. A. D. A. T., Rahman, W. F. W. A., Lazim, N. M., Boer, J. C., Plebanski, M., et al. (2022) · Biology · doi:10.3390/biology11081225 · Cited by 13
Molecular Pathways of Diabetic Kidney Disease Inferred from Proteomics
Wei, L., Han, Y., & Tu, C. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s392888 · Cited by 10
Ostarine-Induced Myogenic Differentiation in C2C12, L6, and Rat Muscles
Leciejewska, N., Kolodziejski, P. A., Sassek, M., Nogowski, L., Małek, E., & Pruszyńska‐Oszmałek, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084404 · Cited by 12
Is There a Role for Hormonal Therapy in Men with Oligoasthenoteratozoospermia (OAT)?
Çayan, S., Altay, B., Rambhatla, A., Colpi, G. M., & Agarwal, A. K. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm14010185 · Cited by 11
Adulteration of Sports Supplements with Anabolic Steroids—From Innocent Athlete to Vicious Cheater
Puscasiu, D. A., Flangea, C., Vlad, D. C., Popescu, R., Vlad, C. S., Barac, S., Rață, A. L., Marina, C. D. L. C., Cobec, I. M., & Laitin, S. M. D. (2025) · Nutrients · doi:10.3390/nu17193146 · Cited by 10
Advances in Interleukin-6 Family Cytokines and the Role in Respiratory Diseases
Ji, T., Huang, G., Cao, Y., Gao, Y., & Gao, X. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s508031 · Cited by 11
Sexual and Reproductive Health Among Men With Cystic Fibrosis
Campbell, K., Zarli, M., Schuppe, K., Wong, R., Rahman, F., & Ramasamy, R. (2023) · Urology · doi:10.1016/j.urology.2023.06.017 · Cited by 8
Zachariou, A., Zikopoulos, A., Markou, E., Koukos, S., Daligkaros, G., Skouros, S., Dimitriadis, F., Chrisofos, M., Sofikitis, N., & Kaltsas, A. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15031204 · Cited by 8
Stocks, B. T., Oppenheimer, A. G., Campbell, K. J., Lindsey, J. P., Kohn, T. P., Alexander, J. M., Huang, J. B., & Lipshultz, L. I. (2024) · Fertility and Sterility · doi:10.1016/j.fertnstert.2024.10.019 · Cited by 12
Functional hypogonadism in men: key causes and neuroendocrine mechanisms of its development
Салухов, В. В., & Витальевна, А. С. (2024) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2024-210 · Cited by 5
Barhouse, P. S., Albright, J. A., Rebello, E., Chang, K., Quinn, M. S., Daniels, A. H., Arcand, M. A., & Gil, J. A. (2024) · The Journal Of Hand Surgery · doi:10.1016/j.jhsa.2024.01.018 · Cited by 6
Liang, Y., Zhong, D., Yang, Q., Tang, Y., Qin, Y., Su, Y., Huang, X., & Shang, J. (2024) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s453249 · Cited by 8
Hu, W., Wang, L., Luo, J., Zhang, J., & Li, N. (2023) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s434973 · Cited by 9
Traitements médicaux de l’homme infertile
Méthorst, C., Faix, A., & Huyghe, É. (2023) · The French Journal of Urology · doi:10.1016/j.purol.2023.09.019 · Cited by 5
Clinical Significance of NAT2 Genetic Variations in Type II Diabetes Mellitus and Lipid Regulation
Jarrar, Y. B., Abudahab, S., Abdul-Wahab, G. A., Zaiter, D., Madani, A., Abaalkhail, S. J., Abulebdah, D., Alhawari, H. H., Mosleh, R., & Lee, S. (2023) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s422495 · Cited by 7
Zhang, Q., Luo, S., Luo, Y., et al. (2023) · Epigenetics · doi:10.1080/15592294.2023.2175168 · Cited by 5
Martinez-Arguelles, D. B., Nedow, J., Gukasyan, H. J., & Papadopoulos, V. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1003017 · Cited by 7
Hypogonadism in male and female: which is the best treatment?
BERTELLI, E., FRENNA, M. D., Cappa, M., Salerno, M., WASNIEWSKA, M., Bizzarri, C., & SANCTIS, L. D. (2021) · Minerva Pediatrics · doi:10.23736/s2724-5276.21.06534-4 · Cited by 8
Diagnosis and treatment of hypogonadism in men seeking to preserve fertility – what are the options?
Lockie, A. W. C., Grice, P., Mathur, R., Pearce, I., & Modgil, V. (2024) · International Journal of Impotence Research · doi:10.1038/s41443-024-00897-4 · Cited by 4
Developments and challenges for new and emergent preparations for male hypogonadism treatment
Corona, G., Sparano, C., Rastrelli, G., Vignozzi, L., & Maggi, M. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2276760 · Cited by 2
Relevance of circulating Semaphorin 4A for rheumatoid arthritis response to treatment
Avouac, J., Vandebeuque, E., Combier, A., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-41943-3 · Cited by 4
Xu, J., Xiao, Y., & Yu, Z.-L. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s573022 · Cited by 8
Medicinal plants from Southeast Asia affecting the reproductive system
Rahmawati, N., Benjamin, M. A. Z., Wahyuni, T. S., Sani, M. H. M., Kadir, A. A., Abdullah, M. N. H., Ahmed, Q. U., & Zakaria, Z. A. (2024) · Food Bioscience · doi:10.1016/j.fbio.2024.105666 · Cited by 5
Quinn, M. S., Albright, A. J., Lemme, N. J., Testa, E. J., Morrissey, P. J., Arcand, M. A., Daniels, A. H., & Fadale, P. D. (2024) · Orthopaedic Journal of Sports Medicine · doi:10.1177/23259671241291063 · Cited by 6
Haider, S. H., Irfan, A., Sheikh, S. M., Abid, M. T., Naz, T., Abbas, M., & Raza, A. (2024) · Future Science OA · doi:10.1080/20565623.2024.2365125 · Cited by 2
Li, B., Zhang, L., Li, Q., Zhang, J., Wang, W., & Quan, J. (2024) · PLoS ONE · doi:10.1371/journal.pone.0308815 · Cited by 4
Long-term use of clomiphene in male macroprolactinomas with persistent hypogonadism
Stumpf, M. A. M., Galliano, S. A., Bueno, C. B. F., & Glezer, A. (2024) · Endocrine · doi:10.1007/s12020-024-03817-0 · Cited by 5
Tang, K., Sun, L., Chen, L., Feng, X., Wu, J., Guo, H., & Zheng, Y. (2024) · International Journal of General Medicine · doi:10.2147/ijgm.s444847 · Cited by 3
Small Molecule Cocktails Promote Fibroblast-to-Leydig-like Cell Conversion for Hypogonadism Therapy
Yuan, F., Bai, K., Hou, Y., Zou, X., & Sun, J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15102456 · Cited by 3
Gao, J. X., Wang, L. H., Li, W., & Liu, W. (2026) · Annals of Medicine · doi:10.1080/07853890.2026.2624183 · Cited by 3
Li, Y., Shi, J., Mei, C., Zhou, F., Zhao, H., & Zhang, L. (2025) · International Journal of General Medicine · doi:10.2147/ijgm.s553709 · Cited by 3
Overview of Clomiphene Citrate Use in Male Hypogonadism and Infertility
Câmara, L. C. (2024) · Asian Journal of Medicine and Health · doi:10.9734/ajmah/2024/v22i121153 · Cited by 2
Bratchikov, O. I., Tyuzikov, I. A., Греков, Е. А., & Смирнов, А. В. (2024) · Andrology and Genital Surgery · doi:10.62968/2070-9781-2024-25-4-15-26 · Cited by 3
Ni, A., Xu, Y., Chen, J., & Han, F. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s494848 · Cited by 5
Wang, Y., Lv, H.-L., He, M., Wu, P., Li, F., & Wang, Y. (2024) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s479131 · Cited by 3
CONDITION OF HYPOTHALAMICPITUITARY- GONADAL SYSTEM IN MILITARY PERSONNEL. LITERATURE REVIEW
Салухов, В. В., Minakov, A. A., & Витальевна, А. С. (2024) · Медицинский вестник МВД · doi:10.52341/20738080_2024_131_4_41 · Cited by 2
Nexus Between Sarcopenia and Microbiome Research: A Bibliometric Exploration
Li, R., Lian, R., Siriwardena, H., Jiang, J., & Yang, M. (2024) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s469747 · Cited by 2
The Role of Testosterone Therapy in Men's Health
Smith, B. K., & Ward, M. P. (2023) · Nursing Clinics of North America · doi:10.1016/j.cnur.2023.07.001 · Cited by 4
Considerations when treating male pubertal delay pharmacologically
Rey, R. A. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2138743 · Cited by 5
Kyzatrex - Oral testosterone replacement therapy
Asghar, A. A., Hashmi, M. R., Ahmed, R., et al. (2022) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2022.104625 · Cited by 2
Wang, D., Zhao, D., & Li, X. (2026) · International Journal of General Medicine · doi:10.2147/ijgm.s600123 · Cited by 1
Methods of correction of hypogonadism syndrome in men and long-term results of drug treatment
Романовна, Р. Е., Rozhivanov, R. V., Морозова, Е. В., Gaidaichuk, K. E., Mel'nichenko, G. A., Andreeva, E. N., & Mokrysheva, N. G. (2025) · Bulletin of Reproductive Health · doi:10.14341/brh12770 · Cited by 1
Zhang, Z., Li, X., Tang, W. J., Xie, H., Wang, H.-J., Xie, H., & Wang, C. (2025) · International Journal of Women s Health · doi:10.2147/ijwh.s551117 · Cited by 1
Wardiyah, H., Rita, R. S., & Tofrizal, T. T. (2024) · International Journal of Research and Review · doi:10.52403/ijrr.20240324
Impact of testosterone levels and testosterone replacement ther-apy on men’s health
Karbowska, Z., Cierpiszewska, K., Maruszczak, K., Sukhachova, I., Szwankowska, D., & Piotrowski, I. (2023) · Journal of Medical Science · doi:10.20883/medical.e856 · Cited by 1
Tienforti, D., Terrana, G., Geronimo, R. D., Perfetto, E., Spagnolo, L., Baroni, M. G., & Barbonetti, A. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02945-w · Cited by 2
Knowledge Mapping of Macrophages in Renal Fibrosis: A Bibliometric Analysis from 2014 to 2025
Hu, D., Fang, J., Cao, X., Hu, M., Meng, H., Xu, J., Jiang, M., & Zhou, W. (2026) · Journal of Inflammation Research · doi:10.2147/jir.s578018
Huijben, M., Prinsen, A., de Kort, L. M. O., & van Breda, J. (2026) · Andrology · doi:10.1111/andr.70226 · Cited by 1
Sang, Z., Chen, J., Chen, W., Sun, B., Zhou, B., Liu, H., & Zhang, H. (2026) · Current Urology · doi:10.1097/cu9.0000000000000350
Khan, S. A., Kadu, P., & Kuppusamy, P. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02329-4
Rabijewski, M., Wydra, J., Kapuściński, G., & Rabijewski, M. (2026) · Polski Merkuriusz Lekarski · doi:10.36740/merkur202602119
Liu, A., Xing, L., Li, J., Yao, M., Song, J., Guo, W., Duan, P., & Li, H. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s590868
Corona, G., Sparano, C., Romeo, M., Sedigh, O., Bettocchi, C., Rastrelli, G., Vignozzi, L., & Maggi, M. (2026) · The World Journal of Men s Health · doi:10.5534/wjmh.260045
Lin, L., Zhang, R., Wang, J., Fan, Y., Xie, W., Yu, B., Lou, J., Pan, Y., Chen, C., Huang, S., et al. (2025) · Clinical Interventions in Aging · doi:10.2147/cia.s553110 · Cited by 1
Strategies for Reversing Exogenous Testosterone-Induced Infertility
Liberto, R., Katlowitz, N. M., Sagalovich, D., & Davila, J. L. (2025) · Cureus · doi:10.7759/cureus.91975 · Cited by 2
Chen, C., & Jiang, Y. (2025) · Journal of Aging and Rehabilitation · doi:10.1097/jagr.0000000000000027
Paudel, H., Nguyen, H. T., Alvi, M. S., et al. (2025) · Cureus · doi:10.7759/cureus.76951
Lin, C.-W., Hung, S., & Chen, I.-W. (2025) · International Journal of General Medicine · doi:10.2147/ijgm.s497664
Various interventions for infertility in men with type II diabetes and hypogonadism
Gourma, D., Kalampokas, E., Triantafyllidou, O., Kalampokas, T., & Vlachos, N. (2024) · Hellenic Journal of Obstetrics and Gynecology · doi:10.33574/hjog.0546
Correlation Between DCAMKL-1 Protein Expression and K-ras Gene Mutation in Colorectal Cancer
Wu, X., Li, S., Yang, Y., Hu, J., & Yang, T. (2024) · Cancer Management and Research · doi:10.2147/cmar.s440845 · Cited by 1
Pathophysiology and Clinical Manifestations of Hypogonadism
Nurma'rifatullah, Duarsa, N. M. M. S. B., Purnama, R. F. N., Khalda, Y. I., & Triani, E. (2023) · JURNAL BIOLOGI TROPIS · doi:10.29303/jbt.v23i1.6189 · Cited by 1
Kamińska, M., Strzoda, A. J., & Polak, A. (2023) · Journal of Health Study and Medicine · doi:10.2478/jhsm-2023-0018
Examining the Efficacy of Clomiphene Citrate as a Treatment for Male Infertility
Rai, R. (2022) · ACTA SCIENTIFIC MICROBIOLOGY · doi:10.31080/asmi.2022.05.1046
Metadata
- Authors
- Ide, V., Vanderschueren, D., & Antonio, L.
- Affiliations
- Universitair Ziekenhuis Leuven (BE)
- Corresponding author
- Antonio, Leen
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-12-22
- Volume
- 22
- Issue
- 1
- Pages
- 21
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7792781
- OpenAlex
- W3114028270
- Cited by
- 101
- References
- 69
- Citations by year
- 2026: 12 · 2025: 15 · 2024: 33 · 2023: 25 · 2022: 11 · 2021: 4 · 2020: 1
- FWCI
- 1.56
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Lirias (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- central hypogonadism, testosterone replacement therapy, alternative treatment, gonadotropins, clomiphene citrate, tamoxifen, male hypogonadism, fertility preservation, off-label drug use, sexual symptoms, testosterone levels
- MeSH terms
- Androgens, Clomiphene, Fertility, Humans, Hypogonadism, Male, Testosterone, Treatment Outcome, Hormone Replacement Therapy, Selective Estrogen Receptor Modulators
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.